Mylan Current Ratio 2006-2018 | MYL

Current and historical current ratio for Mylan (MYL) from 2006 to 2018. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Mylan current ratio for the three months ending June 30, 2018 was 1.30.
Mylan Annual Current Ratio
2017 1.13
2016 1.49
2015 1.57
2014 1.21
2013 1.51
2012 1.78
2011 1.39
2010 1.97
2009 1.91
2008 2.06
2007 1.53
2007 3.44
2006 4.49
2005 6.23
Mylan Quarterly Current Ratio
Q2 2018 1.30
Q1 2018 1.06
Q4 2017 1.13
Q3 2017 1.46
Q2 2017 1.35
Q1 2017 1.56
Q4 2016 1.49
Q3 2016 0.83
Q2 2016 3.23
Q1 2016 1.67
Q4 2015 1.57
Q3 2015 1.76
Q2 2015 1.47
Q1 2015 1.40
Q4 2014 1.21
Q3 2014 1.30
Q2 2014 1.72
Q1 2014 1.64
Q4 2013 1.51
Q3 2013 1.70
Q2 2013 1.81
Q1 2013 1.73
Q4 2012 1.78
Q3 2012 1.73
Q2 2012 1.73
Q1 2012 1.77
Q4 2011 1.39
Q3 2011 1.52
Q2 2011 1.49
Q1 2011 1.57
Q4 2010 1.97
Q3 2010 2.01
Q2 2010 2.23
Q1 2010 2.05
Q4 2009 1.91
Q3 2009 2.06
Q2 2009 2.13
Q1 2009 2.17
Q4 2008 2.06
Q3 2008 1.88
Q2 2008 1.65
Q1 2008 1.57
Q4 2007 1.53
Q3 2007 3.42
Q2 2007 3.16
Q1 2007 3.44
Q4 2006 4.46
Q3 2006 5.13
Q2 2006 4.41
Q1 2006 0.00
Q4 2005 4.45
Q3 2005 4.70
Q2 2005 5.93
Q1 2005 0.00
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $19.184B $11.908B
Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as Mylan Inc., is based in Canonsburg, Pennsylvania.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $62.556B 10.73
Teva Pharmaceutical Industries (TEVA) Israel $23.825B 6.66
Bausch Health Cos (BHC) Canada $7.865B 5.87
Dr Reddy's Laboratories (RDY) India $5.920B 26.44
Mallinckrodt Public Limited Company (MNK) United Kingdom $2.469B 4.20
Supernus Pharmaceuticals (SUPN) United States $2.402B 25.70
Akorn (AKRX) United States $1.667B 8.25
Assembly Biosciences (ASMB) United States $0.876B 0.00
Amphastar Pharmaceuticals (AMPH) United States $0.849B 122.33
Homology Medicines (FIXX) United States $0.750B 0.00
CymaBay Therapeutics (CBAY) United States $0.722B 0.00
Voyager Therapeutics (VYGR) United States $0.603B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.540B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.443B 0.00
Corium (CORI) United States $0.334B 0.00
Teligent (TLGT) United States $0.198B 0.00
Sol-Gel Technologies (SLGL) Israel $0.130B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.117B 0.00
Aevi Genomic Medicine (GNMX) United States $0.077B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.064B 0.00
Evoke Pharma (EVOK) United States $0.056B 0.00
Versartis (VSAR) United States $0.053B 0.00
Acasti Pharma (ACST) Canada $0.020B 0.00
Agile Therapeutics (AGRX) United States $0.013B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.013B 0.00
China Pharma Holdings (CPHI) China $0.009B 0.00